Boron neutron capture therapy for glioblastoma multiforme

Rij, Catharina M. van; Wilhelm, Abraham J.; Sauerwein, W.; Loenen, A. C. Van

doi:10.1007/s11096-004-2850-7

Cited by 34 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This system can transport neutral amino acid analogs containing aromatic side chains [45]. Since human L-type amino acid transport 1 expression is upregulated in a wide range of cancers (including brain tumors), this allows agents like BPA to preferentially accumulate in cancerous tissues compared to surrounding normal tissues [37,46]. Additionally, BPA may preferentially accumulate in brain tumors compared to normal parenchyma due to a compromised BBB integrity within the tumor vasculature [13].…”

Section: Boronophenylalaninementioning

confidence: 99%

“…Leaky tumor vasculature and EPR effect [37,76,77]; cationic liposomes recognize membrane negative charge [79].…”

Section: Cell-membrane Penetrating Peptidesmentioning

confidence: 99%

“…Like nanoparticles, the liposome surface can also be modified to include targeting moieties. Liposomes are believed to accumulate within tumors because of local vasculature leakage known as the enhanced permeability and retention (EPR) effect [37,75]. A majority of solid tumors have a defective blood vessel architecture coupled to an extensive production of vascular permeability factors [76,77].…”

Section: Liposomesmentioning

confidence: 99%

“…The vast majority of patients diagnosed with the aforementioned malignancies undergo palliative care options. To put the severity of these diagnoses into perspective, consider the 2-and 5-year survival rates of newly diagnosed GBM are 10 and 1%, respectively [37]. High grade glioma patients enrolled in BNCT clinical trials have affirmed that BNCT is tolerated well, has comparable (or fewer) side effects than conventional radiation therapy, typically requires only 1-2 treatment sessions, and the median survival times are comparable to standard of care (radiation and temozolomide treatment) [15,38].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

2015

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.

show abstract

Section: Boronophenylalaninementioning

confidence: 99%

“…Leaky tumor vasculature and EPR effect [37,76,77]; cationic liposomes recognize membrane negative charge [79].…”

Section: Cell-membrane Penetrating Peptidesmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

2015

View full text Add to dashboard Cite

show abstract

“…The current standard of care for treating GBM is surgical resection (when operable) followed by radiation therapy (XRT) with concomitant and adjuvant temozolomide treatment (2, 3). Even with this aggressive therapeutic regimen, GBM patients still have a poor prognosis: 2- and 5- year survival rates of 10% and 1%, respectively (4). Current treatment provides only a modest boost to patient survival, and a myriad of radiation- and chemotherapy-induced side effects plague the quality of life for these patients.…”

Section: Introductionmentioning

confidence: 99%

A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma

et al. 2016

View full text Add to dashboard Cite

Purpose Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation has been limited by the poor tumor selectivity of agents. To address this unmet need, a boronated 2-nitroimidazole derivative (B-381) was synthesized and evaluated for its capability of targeting hypoxic glioma cells. Methods B-381 has been synthesized from a 1-step reaction. Using D54 and U87 glioma cell lines, the in vitro cytotoxicity and cellular accumulation of B-381 has been evaluated under normoxic and hypoxic conditions compared to L-boronophenylalanine (BPA). Furthermore, tumor retention of B-381 was evaluated in vivo. Results B-381 had low cytotoxicity in normal and cancer cells. Unlike BPA, B-381 illustrated preferential retention in hypoxic glioma cells compared to normoxic glioma cells and normal tissues in vitro. In vivo, B-381 illustrated significantly higher long-term tumor retention compared to BPA, with 9.5-fold and 6.5-fold higher boron levels at 24 and 48 h, respectively. Conclusions B-381 represents a new class of BNCT agents in which their selectivity to tumors is based on tumor hypoxic metabolism, and further studies are warranted to evaluate this compound and similar compounds as preclinical candidates for future BNCT clinical trials for the treatment of glioma.

show abstract